{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:59Z","timestamp":1791868979625,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Combined radioimmunotherapy (RIT) in follicular lymphomas (FL) has shown promising treatment efficacy in the Mabthera\u00ae and Involved field Radiation (MIR) study. Aim of this study was to analyze treatment efficacy and recurrence patterns after RIT in early-stage nodal and extranodal FL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We reviewed 107 patients who were treated with combined RIT in two centers. Treatment consisted of 4\u202f\u00d7\u2009rituximab followed by RIT with 4\u202f\u00d7\u2009rituximab and involved field (IF) radiotherapy with 30\/40\u202fGy. Median follow-up period was 71\u00a0months. In contrast to the MIR study, extranodal involvement and grade 3A\u00a0histology were included in the analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Extranodal involvement and grade 3A\u00a0histology were present in 21.8% and 13.1%, respectively. Overall response rate (ORR) after 4\u202f\u00d7\u2009rituximab, after completion of RIT, and after 6\u00a0months was 78.1%, 98.8%, and 98.8%, respectively, with increasing rates of complete remissions (CR). Predictive factors associated with superior PFS were tumor size, completely excised lymphomas, and response to first 4\u202f\u00d7\u2009rituximab. 5\u2011year PFS rate was 87.3%, with mostly outfield recurrences (94.1%). Second-line treatment was effective, with 53.3% CR and 46.7% partial remissions (PR). 5\u2011year OS was 98.1%. RIT was tolerated well, with mainly grade 1\u20132 acute side effects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The real-world efficacy of RIT is comparable with the results of the MIR study. Additionally, this analysis shows that extranodal involvement and grade 3A\u00a0histology are not associated with inferior PFS.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00066-020-01624-w","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T17:03:04Z","timestamp":1588784584000},"page":"705-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma"],"prefix":"10.1007","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-6694","authenticated-orcid":false,"given":"Laila","family":"K\u00f6nig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"issue":"12","key":"1624_CR1","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1093\/annonc\/mdx020","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling\u00a0M, Ghielmini\u00a0M, Rule\u00a0S, Salles\u00a0G, Vitolo\u00a0U, Ladetto\u00a0M, Committee\u00a0EG (2017) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(12):3109. https:\/\/doi.org\/10.1093\/annonc\/mdx020","journal-title":"Ann Oncol"},{"issue":"3","key":"1624_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0360-3016(88)90254-4","volume":"14","author":"TS Lawrence","year":"1988","unstructured":"Lawrence\u00a0TS, Urba\u00a0WJ, Steinberg\u00a0SM, Sundeen\u00a0JT, Cossman\u00a0J, Young\u00a0RC, Glatstein\u00a0E (1988) Retrospective analysis of stage I and II indolent lymphomas at the national cancer institute. Int J Radiat Oncol Biol Phys 14(3):417\u2013424","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1624_CR3","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1200\/jco.1996.14.4.1282","volume":"14","author":"MP Mac Manus","year":"1996","unstructured":"Mac Manus\u00a0MP, Hoppe\u00a0RT (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a\u00a0long-term follow-up study of patients treated at Stanford University. J\u00a0Clin Oncol 14(4):1282\u20131290. https:\/\/doi.org\/10.1200\/jco.1996.14.4.1282","journal-title":"J Clin Oncol"},{"issue":"10","key":"1624_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00066-003-1062-8","volume":"179","author":"OJ Ott","year":"2003","unstructured":"Ott\u00a0OJ, Rodel\u00a0C, Gramatzki\u00a0M, Niedobitek\u00a0G, Sauer\u00a0R, Grabenbauer\u00a0GG (2003) Radiotherapy for stage I\u2013III nodal low-grade non-Hodgkin\u2019s lymphoma. Strahlenther Onkol 179(10):694\u2013701. https:\/\/doi.org\/10.1007\/s00066-003-1062-8","journal-title":"Strahlenther Onkol"},{"issue":"12","key":"1624_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s00066-003-1025-0","volume":"179","author":"H Neumann","year":"2003","unstructured":"Neumann\u00a0H, Blanck\u00a0H, Koch\u00a0R, Fiedler\u00a0S, Lesche\u00a0A, Herrmann\u00a0T (2003) Follicle centre lymphoma: treatment results for stage I and II. Strahlenther Onkol 179(12):840\u2013846. https:\/\/doi.org\/10.1007\/s00066-003-1025-0","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"1624_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0167-8140(88)90030-8","volume":"13","author":"P Soubeyran","year":"1988","unstructured":"Soubeyran\u00a0P, Eghbali\u00a0H, Bonichon\u00a0F, Coindre\u00a0JM, Richaud\u00a0P, Hoerni\u00a0B (1988) Localized follicular lymphomas: prognosis and survival of stages I and II in a\u00a0retrospective series of 103 patients. Radiother Oncol 13(2):91\u201398","journal-title":"Radiother Oncol"},{"issue":"12","key":"1624_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2273::AID-CNCR9>3.0.CO;2-V","volume":"80","author":"M Stuschke","year":"1997","unstructured":"Stuschke\u00a0M, Hoederath\u00a0A, Sack\u00a0H, Potter\u00a0R, Muller\u00a0RP, Schulz\u00a0U, Karstens\u00a0J, Makoski\u00a0HB (1997) Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a\u00a0prospective multicenter study. Study Group NHL-fr\u00fche Stadien. Cancer 80(12):2273\u20132284","journal-title":"Cancer"},{"issue":"5","key":"1624_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","volume":"51","author":"RB Wilder","year":"2001","unstructured":"Wilder\u00a0RB, Jones\u00a0D, Tucker\u00a0SL, Fuller\u00a0LM, Ha\u00a0CS, McLaughlin\u00a0P, Hess\u00a0MA, Cabanillas\u00a0F, Cox\u00a0JD (2001) Long-term results with radiotherapy for stage I\u2013II follicular lymphomas. Int J Radiat Oncol Biol Phys 51(5):1219\u20131227","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1624_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF02990087","volume":"11","author":"SM Kelsey","year":"1994","unstructured":"Kelsey\u00a0SM, Newland\u00a0AC, Hudson\u00a0GV, Jelliffe\u00a0AM (1994) A British national Lymphoma investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 11(1):19\u201325","journal-title":"Med Oncol"},{"issue":"3","key":"1624_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S","volume":"44","author":"TG Landberg","year":"1979","unstructured":"Landberg\u00a0TG, Hakansson\u00a0LG, Moller\u00a0TR, Mattsson\u00a0WK, Landys\u00a0KE, Johansson\u00a0BG, Killander\u00a0DC, Molin\u00a0BF, Westling\u00a0PF, Lenner\u00a0PH, Dahl\u00a0OG (1979) CVP-remission-maintenance in stage I or II non-Hodgkin\u2019s lymphomas: preliminary results of a\u00a0randomized study. Cancer 44(3):831\u2013838","journal-title":"Cancer"},{"issue":"2","key":"1624_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0360-3016(80)90027-9","volume":"6","author":"S Monfardini","year":"1980","unstructured":"Monfardini\u00a0S, Banfi\u00a0A, Bonadonna\u00a0G, Rilke\u00a0F, Milani\u00a0F, Valagussa\u00a0P, Lattuada\u00a0A (1980) Improved five year survival after combined radiotherapy-chemotherapy for stage I\u2013II non-Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys 6(2):125\u2013134","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"1624_CR12","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/1097-0142(19930401)71:7<2342::AID-CNCR2820710728>3.0.CO;2-I","volume":"71","author":"J Yahalom","year":"1993","unstructured":"Yahalom\u00a0J, Varsos\u00a0G, Fuks\u00a0Z, Myers\u00a0J, Clarkson\u00a0BD, Straus\u00a0DJ (1993) Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a\u00a0prospective randomized study. Cancer 71(7):2342\u20132350","journal-title":"Cancer"},{"issue":"29","key":"1624_CR13","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus\u00a0M, Fisher\u00a0R, Roos\u00a0D, O\u2019Brien\u00a0P, Macann\u00a0A, Davis\u00a0S, Tsang\u00a0R, Christie\u00a0D, McClure\u00a0B, Joseph\u00a0D, Jayamohan\u00a0J, Seymour\u00a0JF (2018) Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J\u00a0Clin Oncol 36(29):2918\u20132925. https:\/\/doi.org\/10.1200\/JCO.2018.77.9892","journal-title":"J Clin Oncol"},{"issue":"2","key":"1624_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1269\/jrr.47.183","volume":"47","author":"I Skvortsova","year":"2006","unstructured":"Skvortsova\u00a0I, Skvortsov\u00a0S, Popper\u00a0BA, Haidenberger\u00a0A, Saurer\u00a0M, Gunkel\u00a0AR, Zwierzina\u00a0H, Lukas\u00a0P (2006) Rituximab enhances radiation-triggered apoptosis in non-Hodgkin\u2019s lymphoma cells via caspase-dependent and -independent mechanisms. J Radiat Res 47(2):183\u2013196","journal-title":"J. Radiat. Res."},{"issue":"6","key":"1624_CR15","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/hs9.0000000000000160","volume":"2","author":"K Herfarth","year":"2018","unstructured":"Herfarth\u00a0K, Borchmann\u00a0P, Schnaidt\u00a0S, Hohloch\u00a0K, Budach\u00a0V, Engelhard\u00a0M, Viardot\u00a0A, Engenhart-Cabillic\u00a0R, Keller\u00a0U, Reinartz\u00a0G, Eich\u00a0H\u2011T, Witzens-Harig\u00a0M, Hess\u00a0CF, D\u00f6rken\u00a0B, D\u00fcrig\u00a0J, Wiegel\u00a0T, Hiddemann\u00a0W, Hoster\u00a0E, Pott\u00a0C, Dreyling\u00a0M (2018) Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study. Hemasphere 2(6):e160. https:\/\/doi.org\/10.1097\/hs9.0000000000000160","journal-title":"Hemasphere"},{"key":"1624_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2407-11-87","volume":"11","author":"M Witzens-Harig","year":"2011","unstructured":"Witzens-Harig\u00a0M, Hensel\u00a0M, Unterhalt\u00a0M, Herfarth\u00a0K (2011) Treatment of limited stage follicular lymphoma with rituximab immunotherapy and involved field radiotherapy in a\u00a0prospective multicenter phase II trial-MIR trial. BMC Cancer 11:87. https:\/\/doi.org\/10.1186\/1471-2407-11-87","journal-title":"BMC Cancer"},{"issue":"5","key":"1624_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson\u00a0BD, Pfistner\u00a0B, Juweid\u00a0ME, Gascoyne\u00a0RD, Specht\u00a0L, Horning\u00a0SJ, Coiffier\u00a0B, Fisher\u00a0RI, Hagenbeek\u00a0A, Zucca\u00a0E, Rosen\u00a0ST, Stroobants\u00a0S, Lister\u00a0TA, Hoppe\u00a0RT, Dreyling\u00a0M, Tobinai\u00a0K, Vose\u00a0JM, Connors\u00a0JM, Federico\u00a0M, Diehl\u00a0V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J\u00a0Clin Oncol 25(5):579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"issue":"4","key":"1624_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson\u00a0BD, Horning\u00a0SJ, Coiffier\u00a0B, Shipp\u00a0MA, Fisher\u00a0RI, Connors\u00a0JM, Lister\u00a0TA, Vose\u00a0J, Grillo-Lopez\u00a0A, Hagenbeek\u00a0A, Cabanillas\u00a0F, Klippensten\u00a0D, Hiddemann\u00a0W, Castellino\u00a0R, Harris\u00a0NL, Armitage\u00a0JO, Carter\u00a0W, Hoppe\u00a0R, Canellos\u00a0GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI sponsored international working group. J\u00a0Clin Oncol 17(4):1244. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244","journal-title":"J Clin Oncol"},{"issue":"4","key":"1624_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper\u00a0M, Smith\u00a0TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346","journal-title":"Control Clin Trials"},{"issue":"18","key":"1624_CR20","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1002\/cncr.29491","volume":"121","author":"JA Vargo","year":"2015","unstructured":"Vargo\u00a0JA, Gill\u00a0BS, Balasubramani\u00a0GK, Beriwal\u00a0S (2015) What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer 121(18):3325\u20133334. https:\/\/doi.org\/10.1002\/cncr.29491","journal-title":"Cancer"},{"issue":"4","key":"1624_CR21","doi-asserted-by":"publisher","first-page":"iv90","DOI":"10.1093\/annonc\/mdr189","volume":"22","author":"M Engelhard","year":"2011","unstructured":"Engelhard\u00a0M, Unterhalt\u00a0M, Hansmann\u00a0M, Stuschke\u00a0M (2011) Follicular lymphoma: curability by radiotherapy in limited stage nodal disease ? updated results of a\u00a0randomized trial. Ann Oncol 22(4):iv90\u2013iv91. https:\/\/doi.org\/10.1093\/annonc\/mdr189","journal-title":"Ann Oncol"},{"issue":"27","key":"1624_CR22","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1200\/jco.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg\u00a0JW, Byrtek\u00a0M, Link\u00a0BK, Flowers\u00a0C, Taylor\u00a0M, Hainsworth\u00a0J, Cerhan\u00a0JR, Zelenetz\u00a0AD, Hirata\u00a0J, Miller\u00a0TP (2012) Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the national lymphocare study. J\u00a0Clin Oncol 30(27):3368\u20133375. https:\/\/doi.org\/10.1200\/jco.2011.40.6546","journal-title":"J Clin Oncol"},{"issue":"11","key":"1624_CR23","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","volume":"21","author":"JF Seymour","year":"2003","unstructured":"Seymour\u00a0JF, Pro\u00a0B, Fuller\u00a0LM, Manning\u00a0JT, Hagemeister\u00a0FB, Romaguera\u00a0J, Rodriguez\u00a0MA, Ha\u00a0CS, Smith\u00a0TL, Ayala\u00a0A, Hess\u00a0M, Cox\u00a0JD, Cabanillas\u00a0F, McLaughlin\u00a0P (2003) Long-term follow-up of a\u00a0prospective study of combined modality therapy for stage I\u2013II indolent non-Hodgkin\u2019s lymphoma. J\u00a0Clin Oncol 21(11):2115\u20132122. https:\/\/doi.org\/10.1200\/JCO.2003.07.111","journal-title":"J Clin Oncol"},{"issue":"2","key":"1624_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1269\/jrr.46.241","volume":"46","author":"I Skvortsova","year":"2005","unstructured":"Skvortsova\u00a0I, Popper\u00a0BA, Skvortsov\u00a0S, Saurer\u00a0M, Auer\u00a0T, Moser\u00a0R, Kamleitner\u00a0H, Zwierzina\u00a0H, Lukas\u00a0P (2005) Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin\u2019s lymphoma cells. J Radiat Res 46(2):241\u2013248","journal-title":"J. Radiat. Res."},{"issue":"6","key":"1624_CR25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1080\/10428194.2017.1387909","volume":"59","author":"E Cencini","year":"2018","unstructured":"Cencini\u00a0E, Puccini\u00a0B, Rigacci\u00a0L, Fabbri\u00a0A, Kovalchuk\u00a0S, Mannelli\u00a0L, Benelli\u00a0G, Carfagno\u00a0T, Simontacchi\u00a0G, Bocchia\u00a0M, Bosi\u00a0A (2018) Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. Leuk Lymphoma 59(6):1420\u20131426. https:\/\/doi.org\/10.1080\/10428194.2017.1387909","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1624_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","volume":"94","author":"M Ruella","year":"2016","unstructured":"Ruella\u00a0M, Filippi\u00a0AR, Bruna\u00a0R, Di Russo\u00a0A, Magni\u00a0M, Caracciolo\u00a0D, Passera\u00a0R, Matteucci\u00a0P, Di Nicola\u00a0M, Corradini\u00a0P, Parvis\u00a0G, Gini\u00a0G, Olivieri\u00a0A, Ladetto\u00a0M, Ricardi\u00a0U, Tarella\u00a0C, Devizzi\u00a0L (2016) Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I\u2013II follicular lymphoma: results of a\u00a0multicenter study. Int J Radiat Oncol Biol Phys 94(4):783\u2013791. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1624_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-1277-3","author":"L Konig","year":"2018","unstructured":"Konig\u00a0L, Horner-Rieber\u00a0J, Bernhardt\u00a0D, Hommertgen\u00a0A, Rieken\u00a0S, Debus\u00a0J, Herfarth\u00a0K (2018) Response rates and recurrence patterns after low-dose radiotherapy with 4\u202fGy in patients with low-grade lymphomas. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-018-1277-3","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1624_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry\u00a0L, Smith\u00a0P, Qian\u00a0W, Falk\u00a0S, Benstead\u00a0K, Illidge\u00a0T, Linch\u00a0D, Robinson\u00a0M, Jack\u00a0A, Hoskin\u00a0P (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a\u00a0randomised phase III trial. Radiother Oncol 100(1):86\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.013","journal-title":"Radiother Oncol"},{"issue":"1","key":"1624_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","volume":"51","author":"T Girinsky","year":"2001","unstructured":"Girinsky\u00a0T, Guillot-Vals\u00a0D, Koscielny\u00a0S, Cosset\u00a0JM, Ganem\u00a0G, Carde\u00a0P, Monhonval\u00a0M, Pereira\u00a0R, Bosq\u00a0J, Ribrag\u00a0V, Vantelon\u00a0JM, Munck\u00a0JN (2001) A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 51(1):148\u2013155","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"1624_CR30","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RL Haas","year":"2003","unstructured":"Haas\u00a0RL, Poortmans\u00a0P, de Jong\u00a0D, Aleman\u00a0BM, Dewit\u00a0LG, Verheij\u00a0M, Hart\u00a0AA, van Oers\u00a0MH, van der Hulst\u00a0M, Baars\u00a0JW, Bartelink\u00a0H (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J\u00a0Clin Oncol 21(13):2474\u20132480. https:\/\/doi.org\/10.1200\/JCO.2003.09.542","journal-title":"J Clin Oncol"},{"issue":"1","key":"1624_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s13063-019-3614-y","volume":"20","author":"L Konig","year":"2019","unstructured":"Konig\u00a0L, Dreyling\u00a0M, Durig\u00a0J, Engelhard\u00a0M, Hohloch\u00a0K, Viardot\u00a0A, Witzens-Harig\u00a0M, Kieser\u00a0M, Klapper\u00a0W, Pott\u00a0C, Herfarth\u00a0K (2019) Therapy of nodal follicular lymphoma (WHO grade 1\/2) in clinical stage I\/II using response adapted involved site radiotherapy in combination with obinutuzumab (gazyvaro) \u2013 GAZAI trial (GAZyvaro and response adapted involved-site radiotherapy): a\u00a0study protocol for a\u00a0single-arm, non-randomized, open, national, multi-center phase II trial. Trials 20(1):544. https:\/\/doi.org\/10.1186\/s13063-019-3614-y","journal-title":"Trials"},{"issue":"6","key":"1624_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00066-016-0962-3","volume":"192","author":"L Konig","year":"2016","unstructured":"Konig\u00a0L, Stade\u00a0R, Rieber\u00a0J, Debus\u00a0J, Herfarth\u00a0K (2016) Radiotherapy of indolent orbital lymphomas : two radiation concepts. Strahlenther Onkol 192(6):414\u2013421. https:\/\/doi.org\/10.1007\/s00066-016-0962-3","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"1624_CR33","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/hed.24717","volume":"39","author":"CC Pinnix","year":"2017","unstructured":"Pinnix\u00a0CC, Dabaja\u00a0BS, Milgrom\u00a0SA, Smith\u00a0GL, Abou\u00a0Z, Nastoupil\u00a0L, Romaguera\u00a0J, Turturro\u00a0F, Fowler\u00a0N, Fayad\u00a0L, Westin\u00a0J, Neelapu\u00a0S, Fanale\u00a0MA, Rodriguez\u00a0MA, Hagemeister\u00a0F, Lee\u00a0HJ, Oki\u00a0Y, Wang\u00a0M, Samaniego\u00a0F, Chi\u00a0L, Esmaeli\u00a0B (2017) Ultra-low-dose radiotherapy for definitive management of ocular adnexal B\u2011cell lymphoma. Head Neck 39(6):1095\u20131100. https:\/\/doi.org\/10.1002\/hed.24717","journal-title":"Head Neck"},{"issue":"10","key":"1624_CR34","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","volume":"101","author":"R Elstrom","year":"2003","unstructured":"Elstrom\u00a0R, Guan\u00a0L, Baker\u00a0G, Nakhoda\u00a0K, Vergilio\u00a0JA, Zhuang\u00a0H, Pitsilos\u00a0S, Bagg\u00a0A, Downs\u00a0L, Mehrotra\u00a0A, Kim\u00a0S, Alavi\u00a0A, Schuster\u00a0SJ (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101(10):3875\u20133876. https:\/\/doi.org\/10.1182\/blood-2002-09-2778","journal-title":"Blood"},{"issue":"3","key":"1624_CR35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"N Tsukamoto","year":"2007","unstructured":"Tsukamoto\u00a0N, Kojima\u00a0M, Hasegawa\u00a0M, Oriuchi\u00a0N, Matsushima\u00a0T, Yokohama\u00a0A, Saitoh\u00a0T, Handa\u00a0H, Endo\u00a0K, Murakami\u00a0H (2007) The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a\u00a0comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 110(3):652\u2013659. https:\/\/doi.org\/10.1002\/cncr.22807","journal-title":"Cancer"},{"issue":"5","key":"1624_CR36","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/annonc\/mdl014","volume":"17","author":"S Wohrer","year":"2006","unstructured":"Wohrer\u00a0S, Jaeger\u00a0U, Kletter\u00a0K, Becherer\u00a0A, Hauswirth\u00a0A, Turetschek\u00a0K, Raderer\u00a0M, Hoffmann\u00a0M (2006) 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 17(5):780\u2013784. https:\/\/doi.org\/10.1093\/annonc\/mdl014","journal-title":"Ann Oncol"},{"issue":"8","key":"1624_CR37","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","volume":"24","author":"S Luminari","year":"2013","unstructured":"Luminari\u00a0S, Biasoli\u00a0I, Arcaini\u00a0L, Versari\u00a0A, Rusconi\u00a0C, Merli\u00a0F, Spina\u00a0M, Ferreri\u00a0AJ, Zinzani\u00a0PL, Gallamini\u00a0A, Mastronardi\u00a0S, Boccomini\u00a0C, Gaidano\u00a0G, D\u2019Arco\u00a0AM, Di Raimondo\u00a0F, Carella\u00a0AM, Santoro\u00a0A, Musto\u00a0P, Federico\u00a0M (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a\u00a0retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24(8):2108\u20132112. https:\/\/doi.org\/10.1093\/annonc\/mdt137","journal-title":"Ann Oncol"},{"issue":"3","key":"1624_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"JL Brady","year":"2019","unstructured":"Brady\u00a0JL, Binkley\u00a0MS, Hajj\u00a0C, Chelius\u00a0M, Chau\u00a0K, Balogh\u00a0A, Levis\u00a0M, Filippi\u00a0AR, Jones\u00a0M, Mac Manus\u00a0M, Wirth\u00a0A, Oguchi\u00a0M, Vistisen\u00a0AK, Andraos\u00a0TY, Ng\u00a0AK, Aleman\u00a0BMP, Choi\u00a0SH, Kirova\u00a0Y, Hardy\u00a0S, Reinartz\u00a0G, Eich\u00a0HT, Bratman\u00a0SV, Constine\u00a0LS, Suh\u00a0CO, Dabaja\u00a0B, El-Galaly\u00a0TC, Hodgson\u00a0DC, Ricardi\u00a0U, Yahalom\u00a0J, Hoppe\u00a0RT, Mikhaeel\u00a0NG (2019) Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a\u00a0collaborative study by ILROG. Blood 133(3):237\u2013245. https:\/\/doi.org\/10.1182\/blood-2018-04-843540","journal-title":"Blood"},{"key":"1624_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","volume":"126","author":"CL Batlevi","year":"2020","unstructured":"Batlevi\u00a0CL, Sha\u00a0F, Alperovich\u00a0A, Ni\u00a0A, Smith\u00a0K, Ying\u00a0Z, Gerecitano\u00a0JF, Hamlin\u00a0PA, Horwitz\u00a0SM, Joffe\u00a0E, Kumar\u00a0A, Matasar\u00a0MJ, Moskowitz\u00a0AJ, Moskowitz\u00a0CH, Noy\u00a0A, Owens\u00a0C, Palomba\u00a0LM, Straus\u00a0D, von Keudell\u00a0G, Zelenetz\u00a0AD, Seshan\u00a0VE, Luminari\u00a0S, Marcheselli\u00a0L, Federico\u00a0M, Younes\u00a0A (2020) Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer 126:78\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.12.006","journal-title":"Eur J Cancer"},{"issue":"16","key":"1624_CR40","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1002\/cncr.25117","volume":"116","author":"BA Campbell","year":"2010","unstructured":"Campbell\u00a0BA, Voss\u00a0N, Woods\u00a0R, Gascoyne\u00a0RD, Morris\u00a0J, Pickles\u00a0T, Connors\u00a0JM, Savage\u00a0KJ (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 116(16):3797\u20133806. https:\/\/doi.org\/10.1002\/cncr.25117","journal-title":"Cancer"},{"issue":"1","key":"1624_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","volume":"89","author":"T Illidge","year":"2014","unstructured":"Illidge\u00a0T, Specht\u00a0L, Yahalom\u00a0J, Aleman\u00a0B, Berthelsen\u00a0AK, Constine\u00a0L, Dabaja\u00a0B, Dharmarajan\u00a0K, Ng\u00a0A, Ricardi\u00a0U, Wirth\u00a0A, International Lymphoma Radiation Oncology Group (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 89(1):49\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.006","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01624-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-020-01624-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01624-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T23:07:26Z","timestamp":1620256046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-020-01624-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01624-w","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"15 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"K.\u00a0Herfarth reports grants, personal fees, and nonfinancial support from Roche Pharma outside the submitted work. A.\u00a0Viardot reports personal fees from Roche, Amgen, Novartis and\u00a0Gilead outside the submitted work. L.\u00a0K\u00f6nig, J.\u00a0H\u00f6rner-Rieber, S.\u00a0Dietrich, T.\u00a0Wiegel and J.\u00a0Debus declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee (Heidelberg Ethics Committee (S-106\/2019)) and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}